Skip to content

Identification of Clinically Significant Markers of ATTRv in Pre-symptomatic Mutation Carriers.

Identification of Clinically Significant Markers of Hereditary Transthyretin Amyloidosis (TTR) in Pre-symptomatic Mutation Carriers: a Prospective Longitudinal Multicentre Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05754099
Enrollment
20
Registered
2023-03-03
Start date
2022-03-01
Completion date
2024-11-30
Last updated
2023-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyloidosis

Brief summary

The objective of this prospective observational study is to periodically monitor pre-symptomatic subjects carrying a mutation of Transthyretin (TTR), identified in the context of a family screening of affected proband, through instrumental methods and clinical scales in order to identify the first signs of clinically significant organ involvement by the disease. Healthy asymptomatic carriers will be subjected to regular monitoring through clinical evaluations and instrumental investigations defined by the consensus group (Conceicao et al.) in order to validate the criteria defined by this group to define the onset of the disease. A subgroup of carriers with scales and instrumental tests negative for damage to the peripheral nervous system or cardiac, but with subjective symptoms compatible with the disease, will be subjected to further instrumental tests not indicated by consent.

Interventions

None listed

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

1. Pre-symptomatic carriers of TTR mutation in regular follow-up at the Centres. 2. Signature of the written informed consent. 3. Age not less than 10 years compared to the age of onset of the relative with the youngest age of onset and/or a history of bilateral carpal tunnel syndrome undergoing surgery.

Exclusion criteria

* Other causes of neuropathies (diabetes; MGUS; alcoholism; vitamin deficiency). * Other causes of hypertrophic heart disease.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of a cohort of pre-symptomatic subjects carrying a TTR mutation3 yearsTo evaluate in a cohort of pre-symptomatic subjects carrying a TTR mutation the disease onset according to the European consensus criteria (Conceicao et al.).

Countries

Italy

Contacts

Primary ContactMarco Luigetti, MD
marco.luigetti@policlinicogemelli.it0630154303
Backup ContactFlavia Torlizzi
flavia.torlizzi@policlinicogemelli.it0630156433

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026